Safety and Effectiveness of VYC-17.5L for Long-Term Correction of Nasolabial Folds.
Juvéderm Vollure XC (VYC-17.5L; Allergan plc, Dublin, Ireland) belongs to a family of hyaluronic acid (HA) gels based on the Vycross technology platform. Evaluate safety and effectiveness of Vollure for correction of moderate to severe nasolabial folds (NLFs) over 18 months and after repeat treatment. In this prospective, randomized study, subjects (N=123) received initial/touch-up treatment with Vollure in 1 NLF and control filler in the contralateral NLF. Subjects received optional repeat treatment with Vollure after month 12, 15, or 18. Assessments included investigator-rated NLF Severity Scale (NLFSS) responder rates (≥1-point improvement vs baseline); subject-assessed Appraisal of Nasolabial Folds scale of the FACE-Q questionnaire; and subject satisfaction (11-point scale). Median volume of Vollure injected was 1.7 mL for initial/touch-up treatment combined and 0.6 mL for repeat treatment. The NLFSS responder rate was 93%, 85%, and 59% at months 6, 9, and 18 after initial/touch-up treatment, and increased to 94% at 1 month after repeat treatment. Mean subject-reported FACE-Q scores significantly improved from baseline at all timepoints. Most subjects were very satisfied with treatment at all timepoints from day 3 (75%) through month 18 (68%) and at 1 month after repeat treatment (94%). Common injection site responses after initial/touch-up and repeat treatment were firmness, swelling, and tenderness to touch; most were mild/moderate. Vollure was safe and effective for correction of moderate to severe NLFs, with results lasting 18 months in 59% of NLFs. Repeat treatment required one-third of the injection volume to achieve similar improvement in NLF severity as initial/touch-up treatment.